Clinical Trials Sponsored by Arnold Kristof

Total 2987 results

Bristol-Myers Squibb

Completed

A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B

Hepatitis B

Korea, Republic of
Bristol-Myers Squibb

Withdrawn

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Advanced Cancer

Japan
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

Ulcerative Colitis

United States
Bristol-Myers Squibb

Terminated

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Hepatocellular Carcinoma

Canada, Singapore, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC) (ABC)

Rheumatoid Arthritis

Canada
Bristol-Myers Squibb

Completed

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

Atrial Fibrillation
Bristol-Myers Squibb

Completed

Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure

Heart Failure | Atrial Fibrillation

United States
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Bristol-Myers Squibb

Completed

Safety Study of Abatacept in Rheumatoid Arthritis Participants

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

Pattern Of Use Of Belatacept In US Transplant Recipients

Kidney Transplantation: Transplantation, Kidney
Bristol-Myers Squibb

Completed

Treatment of Venous Thromboembolism in Real-Life Patients

Venous Thromboembolism
Bristol-Myers Squibb

Completed

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Thrombosis

United States
Bristol-Myers Squibb

Completed

A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

Hepatitis C

United States, Canada
Bristol-Myers Squibb

Withdrawn

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)

Non-Small Cell Lung Cancer

Argentina, Peru, Germany, United States, Canada
University of Bristol

Completed

Types of Intimate Partner Violence and Women's Health

Domestic Violence
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
University of Bristol

Completed

Lycopene or Green Tea for Men at Risk of Prostate Cancer (ProDiet)

Prostate Cancer

United Kingdom
Bristol-Myers Squibb

Completed

An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Cancer

United States
Bristol-Myers Squibb

Completed

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain
Bristol-Myers Squibb

Completed

Eliquis Regulatory Post Marketing Surveillance

NonValvular Atrial Fibrillation

Korea, Republic of
Bristol-Myers Squibb

Completed

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Psoriasis

Australia
Bristol-Myers Squibb

Completed

Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study (PASS)

Leukemia
Bristol-Myers Squibb

Withdrawn

Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Renal Cell Carcinoma

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Giant Cell Arteritis

Poland, United States, Spain, France, Austria, Belgium, Italy, Romania, Switzerland, Germany, Greece, Netherlands, Australia, Denmark, United Kingdom, Ireland, Bulgaria, Canada, Estonia, Serbia, Sweden
Bristol-Myers Squibb

Completed

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

Thrombosis

United States
Bristol-Myers Squibb

Completed

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Deep Vein Thrombosis | Pulmonary Embolism

Mexico
Bristol-Myers Squibb

Completed

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

Hepatitis C

China, Korea, Republic of, Russian Federation
Bristol-Myers Squibb

Completed

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Head and Neck Cancer | Colorectal Cancer

United States
Bristol-Myers Squibb

Completed

Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

Anticoagulation

France
Bristol-Myers Squibb

Completed

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Thrombosis

United States
Bristol-Myers Squibb

Terminated

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Multiple Myeloma

United States, Italy, France, Spain
Bristol-Myers Squibb

Completed

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant (ALLY 1)

Hepatitis C

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Hepatitis C

France, Australia
Bristol-Myers Squibb

Completed

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis

United States, Portugal, Italy, Brazil, Germany, Peru, France, Spain, Mexico, Austria, Switzerland
Bristol-Myers Squibb

Completed

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

Rheumatoid Arthritis

United Kingdom
Bristol-Myers Squibb

Completed

A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

Renal Transplant

Argentina, Australia, India, United States, Belgium, Brazil, Poland, Mexico, Canada, France, Germany, Spain
Bristol-Myers Squibb

Completed

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

Healthy Subjects

Australia
Bristol-Myers Squibb

Completed

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Arthritis

United States
Bristol-Myers Squibb

Completed

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Chronic Phase Chronic Myeloid Leukemia

France, Italy, United States, Korea, Republic of, Germany
Bristol-Myers Squibb

Completed

Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants

Venous Thromboembolism

United States
Bristol-Myers Squibb

Completed

A Study of the Alternative Administration of Ixabepilone and Vinflunine

Cancer

United States
Bristol-Myers Squibb

Completed

Effect of Ketoconazole on the Pharmacokinetics of Vinflunine

Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects (INH-189-006)

Hepatitis C

United States, Puerto Rico

3

Subscribe